RT Journal Article
SR Electronic
T1 Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.22.20176834
DO 10.1101/2020.08.22.20176834
A1 Patrick J. Tighe
A1 Richard A. Urbanowicz
A1 C. Lucy Fairclough
A1 C. Patrick McClure
A1 Brian J. Thomson
A1 Nancy Gomez
A1 Joseph G. Chappell
A1 Theocharis Tsoleridis
A1 Matthew Loose
A1 Matthew Carlile
A1 Christopher Moore
A1 Nadine Holmes
A1 Fei Sang
A1 Divyateja Hrushikesh
A1 Gemma Clark
A1 Nigel Temperton
A1 Tim Brooks
A1 Jonathan K. Ball
A1 William L. Irving
A1 Alexander W. Tarr
YR 2020
UL http://medrxiv.org/content/early/2020/08/24/2020.08.22.20176834.abstract
AB COVID-19 continues to cause a pandemic, having infected more than 20 million people globally. Successful elimination of the SARS-CoV-2 virus will require an effective vaccine. However, the immune correlates of infection are currently poorly understood. While neutralizing antibodies are believed to be essential for protection against infection, the contribution of the neutralizing antibody response to resolution of SARS-CoV-2 infection has not yet been defined. In this study the antibody responses to the SARS-CoV-2 spike protein and nucleocapsid proteins were investigated in a UK patient cohort, using optimised immunoassays and a retrovirus-based pseudotype entry assay. It was discovered that in severe COVID-19 infections an early antibody response to both antigens was associated with improved prognosis of infection. While not all SARS-CoV-2-reactive sera were found to possess neutralizing antibodies, neutralizing potency of sera was found to be greater in patients who went on to resolve infection, compared with those that died from COVID-19. Furthermore, viral genetic variation in spike protein was found to influence the production of neutralizing antibodies. Infection with the recently described spike protein variant 614G produced higher levels of neutralizing antibodies when compared to viruses possessing the 614D variant. These findings support the assertion that vaccines targeting generation of neutralizing antibodies may be useful at limiting SARS-CoV-2 infection. Assessment of the antibody responses to SARS-CoV-2 at time of diagnosis will be a useful addition to the diagnostic toolkit, enabling stratification of clinical intervention for severe COVID-19 disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project received funding from the University of Nottingham Campaign and Alumni Relations Office and an MRC Confidence in Concept award. Whole genome sequencing of SARS-CoV-2 was funded by COG-UK; COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was ethically assessed in line with the University of Nottingham's Code of Research Conduct and Research Ethics and in line with School of Life Sciences Research Ethics Committee (SLSREC) guidelines. Following assessment by SLSREC, this project did not raise any ethical concerns to warrant a full ethics committee review. The study was assessed in line with data protection regulations; the samples used were fully anonymised from the source and the study did not pose any potential risks with regards to the identity of individual donors. Advice was sought from the University of Nottingham Human Tissue Management Group and given the samples were cell-free serum it was concluded they were not Relevant Materials in line with the Human Tissue Authority guidance. Local established health and safety procedures and guidelines were followed throughout the conduct of this study. Sampling of material containing SARS-CoV-2 for viral genome sequencing was performed as part of the COVID-19 UK Genomics Consortium (COG-UK), with ethical approvial provided by Public Health England's Research Ethics and Governance Group (REGG)(ref.NR0195). Control COVID-19 negative samples were collected as part of the Trent HCV cohort study. Ethical approval for the Trent cohort study was granted by the Northern & Yorkshire Multicentre ResearchEthics Committee (MREC/98/3/55) and patients provided serum samples with informed consent. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data is available on request